Abstract
One mechanism leading to neurodegeneration during Alzheimers Disease (AD) is amyloid β peptide (Aβ)- induced neurotoxicity. Among the factors proposed to potentiate Aβ toxicity is its covalent modification through carbohydrate- derived advanced glycation endproducts (AGEs). Other experimental evidence, though, indicates that certain polymeric carbohydrates like the glycosaminoglycan (GAG) chains found in proteoglycan molecules attenuate the neurotoxic effect of Aβ in primary neuronal cultures. Pretreatment of the 42-residue Aβ fragment (Aβ1-42) with the ubiquitous brain carbohydrates, glucose, fructose, and the GAG chondroitin sulfate B (CSB) inhibits Aβ1-42-induced apoptosis and reduces the peptide neurotoxicity on neuroblastoma cells, a cytoprotective effect that is partially reverted by AGE inhibitors such as pyridoxamine and L-carnosine. Thioflavin T fluorescence measurements indicate that at concentrations close to physiological, only CSB promotes the formation of Aβ amyloid fibril structure. Atomic force microscopy imaging and Western blot analysis suggest that glucose favours the formation of globular oligomeric structures derived from aggregated species. Our data suggest that at short times carbohydrates reduce Aβ1-42 toxicity through different mechanisms both dependent and independent of AGE formation.
Keywords: Alzheimer's disease, advanced glycation endproducts, amyloid fibrils, amyloid β peptide, apoptosis, carbohydrates, glycosaminoglycans
Current Alzheimer Research
Title: Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Volume: 7 Issue: 5
Author(s): X. Fernandez-Busquets, J. Ponce, R. Bravo, M. Arimon, T. Martianez, A. Gella, J. Cladera and N. Durany
Affiliation:
Keywords: Alzheimer's disease, advanced glycation endproducts, amyloid fibrils, amyloid β peptide, apoptosis, carbohydrates, glycosaminoglycans
Abstract: One mechanism leading to neurodegeneration during Alzheimers Disease (AD) is amyloid β peptide (Aβ)- induced neurotoxicity. Among the factors proposed to potentiate Aβ toxicity is its covalent modification through carbohydrate- derived advanced glycation endproducts (AGEs). Other experimental evidence, though, indicates that certain polymeric carbohydrates like the glycosaminoglycan (GAG) chains found in proteoglycan molecules attenuate the neurotoxic effect of Aβ in primary neuronal cultures. Pretreatment of the 42-residue Aβ fragment (Aβ1-42) with the ubiquitous brain carbohydrates, glucose, fructose, and the GAG chondroitin sulfate B (CSB) inhibits Aβ1-42-induced apoptosis and reduces the peptide neurotoxicity on neuroblastoma cells, a cytoprotective effect that is partially reverted by AGE inhibitors such as pyridoxamine and L-carnosine. Thioflavin T fluorescence measurements indicate that at concentrations close to physiological, only CSB promotes the formation of Aβ amyloid fibril structure. Atomic force microscopy imaging and Western blot analysis suggest that glucose favours the formation of globular oligomeric structures derived from aggregated species. Our data suggest that at short times carbohydrates reduce Aβ1-42 toxicity through different mechanisms both dependent and independent of AGE formation.
Export Options
About this article
Cite this article as:
Fernandez-Busquets X., Ponce J., Bravo R., Arimon M., Martianez T., Gella A., Cladera J. and Durany N., Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383787
DOI https://dx.doi.org/10.2174/156720510791383787 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests
Current Cancer Drug Targets Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry A Review on Melatonin’s Effects in Cancer: Potential Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors
Current Cancer Drug Targets KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma
Letters in Drug Design & Discovery Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design